F-18 AV 1451
PreclinicalSmall molecule
F-18 AV 1451 is one of 11 small molecule programs targeting Atypical Alzheimer's Disease. It is currently in Preclinical.
2
Indications
4
Total Trials
3
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Progressive Supranuclear Palsy
#DrugCompanyPhaseTrials
1Ambien
PPurdue Pharma LP
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Rilutek
AAzurity Pharmaceuticals
Approved
AMX0035
AAmylyx Pharmaceuticals Inc.
Phase 3
Kynmobi
SSamson Clinical Operations Pty Ltd
Preclinical
LM11A-31
AAdam Boxer
Phase 2
Aadvac1
AAxon Neuroscience SE
Phase 2
UCB0107
UCBPhase 1
Tideglusib
AAMO Pharma Limited
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Frontotemporal Dementia1 trial
Progressive Supranuclear Palsy1 trial
Atypical Alzheimer's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-18 AV 1451. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMayo Clinic